CORE FACILITY-COLON ONCOLOGY is included in the project entitled: 'DNA Topoisomerase I-Targeted Therapy of Colonic Cancer'. A tissue depository ('Human Tissue Band""""""""), which is part of the facility, is essential for the following aims of the Proposal: 1. To select patients with adenocarcinoma of the colon and obtain their pathologic and normal colonic tissues for laboratory studies. 2. To maintain the Human Tissue Bank as a source of clinical material for research on molecular, cellular and tumor biology of DNA topoisomerase I. 3. To organize a patient data base, which will be used to correlate laboratory and clinical findings. This part of the project has been initiated, and the results of investigations are reported under Preliminary Studies. The overall objectives will be met by the end of the 02 year of support. In year 02- 03, two additional objectives will be accomplished: 4. To prepare the Investigational New Drug (IND) application to the US Food and Drug Administration. The application will be based on Project studies of one or several leading analogs, as well as on toxicology and pharmacology research done independently outside this Project. 5. To prepare a Phase-I protocol for initial clinical research of leading analog(s) discovered in the Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA050529-04
Application #
3751187
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Sewak, Sanjeev; Sorich, Joan; O'Leary, James (2006) Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs 17:571-9
O'Leary, J J; Shapiro, R L; Ren, C J et al. (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5:181-7
Potmesil, M; Arbuck, S G; Takimoto, C H et al. (1996) 9-Aminocamptothecin and beyond. Preclinical and clinical studies. Ann N Y Acad Sci 803:231-46
Wall, M E; Wani, M C (1996) Camptothecin. Discovery to clinic. Ann N Y Acad Sci 803:1-12
D'Arpa, P; Liu, L F (1995) Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Res 217:125-31
Newcomb, E W; Thomas, A; Selkirk, A et al. (1995) Frequent homozygous deletions of D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res 55:2044-7
Bodley, A L; Wani, M C; Wall, M E et al. (1995) Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 50:937-42
Potmesil, M; Vardeman, D; Kozielski, A J et al. (1995) Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55:5637-41
Pantazis, P; Kozielski, A; Rodriguez, R et al. (1994) Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4:5-10
Potmesil, M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54:1431-9

Showing the most recent 10 out of 17 publications